首页> 外文期刊>Genetic testing and molecular biomarkers >Polymorphism of ERCC2 Asp312Asn with Lung Cancer Risk: Evidence from 20,101 Subjects
【24h】

Polymorphism of ERCC2 Asp312Asn with Lung Cancer Risk: Evidence from 20,101 Subjects

机译:ERCC2 Asp312Asn多态性与肺癌风险的关系:来自20,101名受试者的证据

获取原文
获取原文并翻译 | 示例
       

摘要

The association between excision repair cross complementing group 2 (ERCC2) Asp312Asn polymorphism and lung cancer has been reported by many articles recently, but the results were controversial and inconclusive. Therefore, a meta-analysis was conducted to assess the relationship between them. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. A total of 22 full studies with 20,101 subjects (8719 cases and 11,382 controls) were included in our research. The meta-analysis result showed that no significant association was found between ERCC2 Asp312Asn polymorphism and lung cancer in overall analysis (AA vs. GG, OR=1.023, 95% CI = 0.824-1.270, p = 0.838; AG vs. GG, OR=1.003, 95% CI = 0.936-1.074, p = 0.942; AA + AG vs. GG, OR=1.013, 95% CI=0.949-1.082, p = 0.697; AA vs. AG + GG, OR=1.033, 95% CI = 0.841-1.270, p = 0.755). In subset analyses of stratified ethnicity, significantly increased risk was found among Asians (AA vs. GG, OR=3.212, 95% CI = 1.518-6.795, p = 0.002; AA vs. AG + GG, OR=3.174, 95% CI = 1.500-6.712, p = 0.003), whereas the association was not found among Caucasians under any genetic models. When analyses were conducted based on the study design, it indicated that the risk of lung cancer might be significantly increased in a hospital-based study (AA vs. GG, OR = 1.323, 95% CI = 1.096-1.596, p = 0.004; AA + AG vs. GG, OR=1.109, 95% CI = 1.000-1.229, p = 0.050; AA vs. AG + GG, OR= 1.285, 95% CI = 1.076-1.535, p = 0.006). In addition, a significantly increased risk for nonsmokers was detected under the dominant model (AA + AG vs. GG, OR = 1.460, 95% CI = 1.095-1.948, p = 0.010). In conclusion, this meta-analysis suggested ERCC2 Asp312Asn polymorphism may increase the risk of lung cancer among Asians, whereas not among Caucasians.
机译:最近有许多文章报道了切除修复交叉互补第二组(ERCC2)Asp312Asn多态性与肺癌之间的关联,但结果尚有争议且无定论。因此,进行了荟萃分析以评估它们之间的关系。具有95%置信区间(CI)的合并比值比(OR)用于评估关联强度。总共22项针对20,101名受试者(8719例病例和11,382名对照)的完整研究纳入了我们的研究。荟萃分析结果表明,在总体分析中,ERCC2 Asp312Asn多态性与肺癌之间没有显着相关性(AA与GG,OR = 1.023,95%CI = 0.824-1.270,p = 0.838; AG与GG,OR = 1.003,95%CI = 0.936-1.074,p = 0.942; AA + AG vs.GG,OR = 1.013,95%CI = 0.949-1.082,p = 0.697; Aa vs.AG + GG,OR = 1.033,95 %CI = 0.841-1.270,p = 0.755)。在分层种族的子集分析中,发现亚洲人的风险显着增加(AA vs. GG,OR = 3.212,95%CI = 1.518-6.795,p = 0.002; AA vs. AG + GG,OR = 3.174,95%CI = 1.500-6.712,p = 0.003),而在任何遗传模型下,白种人之间均未发现这种关联。当基于研究设计进行分析时,它表明在一项基于医院的研究中肺癌的风险可能会显着增加(AA与GG,OR = 1.323,95%CI = 1.096-1.596,p = 0.004; AA + AG vs.GG,OR = 1.109,95%CI = 1.000-1.229,p = 0.050; Aa vs.AG + AG,OR = 1.285,95%CI = 1.076-1.53​​5,p = 0.006)。此外,在主导模型下检测到非吸烟者的风险显着增加(AA + AG与GG,OR = 1.460,95%CI = 1.095-1.948,p = 0.010)。总之,这项荟萃分析表明,ERCC2 Asp312Asn多态性可能会增加亚洲人中患肺癌的风险,而不是白种人中。

著录项

  • 来源
    《Genetic testing and molecular biomarkers》 |2014年第1期|50-56|共7页
  • 作者单位

    Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Oncology, Cancer Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, China;

    Department of Cardiothoracic Surgery First Affiliated Hospital Guangxi Medical University Guangxi Nanning 530021 China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:16:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号